FDA Brief

Warning letters Drugs

FDA warning letter to

Amman Pharmaceutical Industries

High riskIssued Feb 14, 2024Posted Feb 27, 2024Center for Drug Evaluation and Research | CDER

FDA warned Amman Pharmaceutical Industries after a 2023 inspection found sterile drug manufacturing and data integrity failures.

What happened

FDA inspected the Amman, Jordan contract manufacturer of sterile OTC and homeopathic drugs from August 7 to 15, 2023. Investigators found deficient sterile manufacturing facility and equipment design, inadequate environmental and personnel monitoring, poor sterile technique, and equipment not sterilized. FDA also found unreliable laboratory records, overwritten laboratory equipment data, and quality unit oversight failures.

What FDA found

  1. The sterile manufacturing areas and equipment were poorly designed and required many manual interventions that threatened product sterility.

    21 CFR 211.42(c)(10)
  2. Environmental and personnel monitoring were inadequate, and airflow was not studied under production conditions.

    21 CFR 211.42(c)(10)
  3. The company lacked adequate procedures to prevent microbial contamination and shipped sterile products before performing process simulations (media fills).

    21 CFR 211.113(b)
  4. Operators used poor sterile technique and cleanroom behavior during filling.

    21 CFR 211.113(b)
  5. Equipment touching sterile product parts was not sterilized.

    21 CFR 211.113(b)
  6. Laboratory records were incomplete or unreliable, including missing microbial results and overwritten laboratory equipment data.

    21 CFR 211.194(a)

What FDA wants

FDA asks the company to provide comprehensive independent contamination risk assessments, detailed remediation and corrective action plans, an independent environmental monitoring assessment, a data integrity investigation, and a quality unit remediation plan. No response deadline is stated in the letter.

Who should pay attention

  • U.S. companies that buy sterile OTC or homeopathic drugs from this contract manufacturer
  • brands relying on sterile contract manufacturing
  • quality teams overseeing sterile drug suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk